Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
1.941
+0.021 (1.09%)
At close: Nov 13, 2026, 4:00 PM EST
1.920
-0.021 (-1.08%)
After-hours: Nov 13, 2026, 7:30 PM EST
Propanc Biopharma Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 0.26 | 0.83 | 0.01 | 0.02 | 0.01 | 0 |
Cash & Short-Term Investments | 0.26 | 0.83 | 0.01 | 0.02 | 0.01 | 0 |
Cash Growth | -57.14% | 6782.91% | -42.67% | 109.86% | 147.04% | 80.36% |
Other Receivables | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
Receivables | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
Prepaid Expenses | 7.67 | 7.66 | 8.33 | - | 0.01 | 0.01 |
Other Current Assets | 0.05 | 0.03 | 0 | 0 | - | - |
Total Current Assets | 8 | 8.54 | 8.35 | 0.03 | 0.02 | 0.02 |
Property, Plant & Equipment | 0.04 | 0.04 | 0.06 | 0.02 | 0.04 | 0.06 |
Long-Term Deferred Charges | - | - | 0.29 | 0.03 | - | - |
Other Long-Term Assets | 2.29 | 4.19 | 10.93 | 0 | 0 | 0 |
Total Assets | 10.33 | 12.78 | 19.63 | 0.07 | 0.06 | 0.08 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 1.16 | 1.13 | 1.25 | 1.21 | 0.97 | 0.94 |
Accrued Expenses | 1.69 | 1.74 | 2.35 | 1.53 | 1.21 | 0.94 |
Short-Term Debt | 0.36 | 0.46 | 1.56 | 0.87 | 0.51 | 0.98 |
Current Portion of Leases | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
Other Current Liabilities | - | - | 0.4 | 0.16 | 0.45 | 0.18 |
Total Current Liabilities | 3.24 | 3.35 | 5.58 | 3.79 | 3.16 | 3.06 |
Long-Term Debt | - | - | 0.11 | 0.06 | - | - |
Long-Term Leases | 0.02 | 0.02 | 0.04 | - | 0.02 | 0.04 |
Total Liabilities | 3.26 | 3.38 | 5.73 | 3.85 | 3.18 | 3.11 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 0 | 0 | 0 | 0 | 0.01 | 0 |
Additional Paid-In Capital | 159.55 | 152.75 | 138.25 | 61.7 | 60.31 | 57.36 |
Retained Earnings | -153.07 | -144.48 | -125.62 | -66.7 | -64.68 | -61.56 |
Treasury Stock | -0.55 | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
Comprehensive Income & Other | 1.14 | 1.18 | 1.32 | 1.27 | 1.29 | 1.21 |
Total Common Equity | 7.07 | 9.4 | 13.91 | -3.78 | -3.12 | -3.03 |
Shareholders' Equity | 7.07 | 9.4 | 13.91 | -3.78 | -3.12 | -3.02 |
Total Liabilities & Equity | 10.33 | 12.78 | 19.63 | 0.07 | 0.06 | 0.08 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 0.41 | 0.51 | 1.73 | 0.95 | 0.55 | 1.04 |
Net Cash (Debt) | -0.15 | 0.32 | -1.71 | -0.93 | -0.54 | -1.04 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.54 | 2.87 | -108.03 | - | - | - |
Filing Date Shares Outstanding | 1.05 | 0.63 | 0.05 | - | - | - |
Total Common Shares Outstanding | 0.98 | 0.33 | 0.05 | - | - | - |
Working Capital | 4.76 | 5.19 | 2.77 | -3.77 | -3.14 | -3.05 |
Book Value Per Share | 7.19 | 28.40 | 299.40 | - | - | - |
Tangible Book Value | 7.07 | 9.4 | 13.91 | -3.78 | -3.12 | -3.03 |
Tangible Book Value Per Share | 7.19 | 28.40 | 299.40 | - | - | - |
Machinery | - | 0.03 | 0.03 | - | 0.03 | 0.03 |